
Opinion|Videos|February 28, 2025
Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in the frontline setting, by offering effective, targeted therapy that provides significant clinical benefits and improves overall survival compared with traditional chemotherapy.
Advertisement
Episodes in this series

- How have BTK inhibitors transformed the treatment paradigm for patients with CLL and MCL, particularly in the frontline setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Sexual Dysfunction From Cancer Is Widespread—and Many Don’t Know That Before Treatment, Data Show
3
Enzalutamide Combo Improves OS in Prostate Cancer Without Sacrificing Quality of Life: Stephen Freedland, MD
4
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
5